RC-118

N/A

Report date: 2025/10/10 17:48:45

Base Information

Drug NameRC-118
Drug Alias NameRC-118YH005 ADC
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRemeGen Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesRemeGen Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A